TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03342235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive Keratectomy (PRK)
Description: Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching 2 hours per day
Description: Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser System
Description: Excimer Laser System for use in photorefractive keratectomy.
Study: NCT03668951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine buccal
Description: DEX 2 mcg/kg buccal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Intranasal
Description: DEX 3 mcg/kg intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Intranasal
Description: DEX 4 mcg/kg intranasal
Study: NCT01885351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCRCS+Prefs
Description: Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCRCS+Prefs+Barriers
Description: Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers.
Study: NCT01073345

Intervention type: PROCEDURE
Intervention: Portal venous pressure
Description: Portal venous pressure is measured by invasive means using an arterial canula

Intervention type: PROCEDURE
Intervention: Portal venous pressure
Description: Portal venous pressure is measured by invasive means using an arterial canula
Study: NCT02573740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-957

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02939690

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVC
Description: UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVC
Description: UVC insertion depth calculated by umbilicus to nipple distance-1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT03930251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Based Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial-Remote Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
Study: NCT01024777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
Study: NCT02090231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS, Magstim Rapid2
Description: 5 Hz rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS, Magstim Rapid2
Description: 5 Hz rTMS
Study: NCT04028856

Intervention type: DRUG
Intervention: interferon
Description: Chronic hepatitis B patients were treated with interferon for 48 weeks

Intervention type: DRUG
Intervention: interferon
Description: Chronic hepatitis B patients were treated with interferon for 48 weeks
Study: NCT02827396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions.
Study: NCT05568316

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Immunonutrition
Description: Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Perioperative Immunonutrition
Description: Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.
Study: NCT04429867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
Study: NCT01418950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written information and verbal counseling
Description: control group will only receive verbal counseling. Study group will receive written information before verbal counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information and verbal counseling
Description: control group will only receive verbal counseling. Study group will receive written information before verbal counseling
Study: NCT02871050

Intervention type: OTHER
Intervention: Sample Collection
Description: Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
Study: NCT02951195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-152
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-152
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-152
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-152
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-152
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-152.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-152.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-152/TEZ/IVA triple combination (TC).
Study: NCT05632796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.
Description: All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
Study: NCT03380130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: An anti-programmed death 1 monoclonal antibody

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
Study: NCT03623893

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contralateral exploration
Description: Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
Study: NCT00879541

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biostate® [SP]
Description: Single bolus intravenous dose of 50 IU/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate® [SP]
Description: The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biostate® [RP]
Description: Single bolus intravenous dose of 50 IU/kg.
Study: NCT02857387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample withdrawn
Study: NCT00566280

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Breast Imaging
Description: A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
Study: NCT03290313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shu gan yi yang capsule
Description: Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: shu gan yi yang capsule simulation agent
Description: Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive psychotherapy
Description: Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
Study: NCT03108274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Oral tablet.
Study: NCT03109730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: An antiviral medication used in the treatment of hepatitis B virus infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: An antiviral medication used in the treatment of hepatitis B virus infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Used to treat adults with chronic hepatitis B virus who show signs of liver damage
Study: NCT04915898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene - teeth brushing
Description: Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
Study: NCT02328183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
Study: NCT01512212

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: biopsy
Description: fnab
Study: NCT00850070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin
Description: Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
Study: NCT00020683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incyclinide
Description: High dose given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incyclinide
Description: Low dose given orally
Study: NCT01656304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00020683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02949648

Intervention type: DEVICE
Intervention: Electronic cigarette
Description: Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
Study: NCT00322699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole bladder laser light treatment as an alternative to radical cystectomy
Description: The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
Study: NCT01073345

Intervention type: PROCEDURE
Intervention: Portal venous pressure
Description: Portal venous pressure is measured by invasive means using an arterial canula

Intervention type: PROCEDURE
Intervention: Portal venous flow
Description: Portal venous flow is measures using a noninvasive method (Doppler flow meter)

Intervention type: PROCEDURE
Intervention: Portal venous flow
Description: Portal venous flow is measures using a noninvasive method (Doppler flow meter)

Intervention type: PROCEDURE
Intervention: Portal venous flow
Description: Portal venous flow is measures using a noninvasive method (Doppler flow meter)
Study: NCT00322699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin
Description: The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
Study: NCT04159155

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Description: Radiation therapy given outside the patient to a particular part of the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral drug

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal high-dose rate brachytherapy
Description: Internal radiation to the vagina
Study: NCT01073345

Intervention type: PROCEDURE
Intervention: Hepatic artery flow
Description: Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)

Intervention type: PROCEDURE
Intervention: Hepatic artery flow
Description: Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)

Intervention type: PROCEDURE
Intervention: Hepatic artery flow
Description: Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)